Understand the source comparison
Peptides for Sleep Quality: Clinical Evidence Comparison
DSIP (Delta Sleep-Inducing Peptide) Increases slow-wave sleep duration; modulates serotonin and GABA activity in the thalamus 12–18 minute reduction in sleep latency (Schneider-Helmert, 1981) Increases slow-wave sleep by 31%; reduces nighttime awakenings by 42
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- DSIP (Delta Sleep-Inducing Peptide)
- Increases slow-wave sleep duration; modulates serotonin and GABA activity in the thalamus
- 12–18 minute reduction in sleep latency (Schneider-Helmert, 1981)
- Increases slow-wave sleep by 31%; reduces nighttime awakenings by 42% (Peptides, 1984)
- Multiple controlled trials in the 1980s; limited replication in modern research
- Most evidence dates to early peptide research era. Mechanism is plausible but requires contemporary validation
- Selank
- GABAergic modulation; reduces anxiety-related sleep disruption
- 22% reduction in sleep onset latency in GAD patients (Neuroscience and Behavioral Physiology, 2019)
- Increases slow-wave sleep by 14%; no REM suppression
- Randomised controlled trials in anxiety populations; direct sleep trials limited
- Strong anxiolytic evidence; sleep improvement appears secondary to reduced arousal rather than direct sleep induction
- Epithalon
- Regulates circadian clock genes; normalises cortisol diurnal rhythm
- Indirect. Restores evening cortisol decline within 10–14 days
- Normalises REM/slow-wave proportions in disrupted sleepers
- Russian clinical trials (Khavinson et al.); limited Western replication
- Promising circadian rhythm restoration mechanism; most evidence from non-English literature
- Thymalin
- Immune modulation; reduces inflammatory cytokine-driven sleep disruption
- Not directly measured in trials
- Potentially improves sleep in autoimmune or chronic inflammation contexts
- Thymic peptide research focuses on immune outcomes, not sleep-specific endpoints
- Sleep benefit would be indirect via inflammation reduction. No controlled sleep trials exist
- Cerebrolysin
- Neurotrophic support; BDNF upregulation
- Not established as a sleep aid
- May improve sleep in neurodegenerative contexts (stroke recovery, TBI)
- Clinical use in stroke and dementia; sleep as secondary outcome only
- Not a sleep-specific peptide. Any benefit likely relates to neurological recovery